Sugi K, Mori F, Miyamoto M, Esato K
First Department of Surgery, Yamaguchi University of Medicine, Ube, Japan.
Nihon Kyobu Geka Gakkai Zasshi. 1990 Aug;38(8):1278-83.
The combined effect of the residual propranolol, which was administrated up to the coronary revasculization, and verapamil, anti-supraventricular tachycardia drug, on the left ventricular contractility was evaluated with left ventricular end-systolic pressure-diameter relationship. Methods; Eighteen sheep were instrumented with ultrasonic crystals on the anterior and posterior wall, endocardium and epicardium. A pressure transducer was placed in the left ventricle. Propranolol (0.15 mg/kg) (n = 6) or verapamil (0.15 mg/kg) (n = 6) or both drugs (n = 6) were administrated intravenously, and cardiac function was evaluated. Results; In combined group, end-systolic pressure-diameter ratio (Emax) was significantly decreased (2.95 +/- 0.24 mmHg/mm) as compared to the control group (7.95 +/- 0.83), propranolol group (6.27 +/- 0.78), and verapamil group (4.54 +/- 0.77). Conclusion; Co-existence of propranolol and verapamil significantly decreased cardiac contractility. Therefore verapamil should be administrated carefully in the presence of residual propranolol, and the co-existence of both drugs must be limited.
通过左心室收缩末期压力-直径关系评估直至冠状动脉血运重建时给予的残留普萘洛尔与抗室上性心动过速药物维拉帕米对左心室收缩性的联合作用。方法：18只绵羊在其前壁和后壁、心内膜和心外膜植入超声晶体。在左心室内放置一个压力传感器。静脉给予普萘洛尔（0.15mg/kg）（n = 6）或维拉帕米（0.15mg/kg）（n = 6）或两种药物（n = 6），并评估心脏功能。结果：联合用药组的收缩末期压力-直径比值（Emax）为（2.95±0.24mmHg/mm），与对照组（7.95±0.83）、普萘洛尔组（6.27±0.78）和维拉帕米组（4.54±0.77）相比显著降低。结论：普萘洛尔和维拉帕米同时存在会显著降低心脏收缩性。因此，在有残留普萘洛尔的情况下应谨慎使用维拉帕米，且两种药物同时存在的情况必须受到限制。
